Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday
Akebia Therapeutics (AKBA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts expecting earnings of ($0.03) per share and revenue of $48.37 million. The stock traded down to $1.17, with a market cap of $309 million, and faces mixed analyst sentiment though the consensus is a "Moderate Buy" with an average target of $5.60. Recent insider selling by the CAO and institutional ownership around 33.9% were also noted.
Akebia Therapeutics to Report Fourth Quarter and Full Year
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026. The company will host a conference call on the same day at 8:00 a.m. EST to discuss these results and recent business highlights. Interested parties can register for the call via a provided link or access a live webcast on Akebia’s investor relations website.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, before the financial markets open. The company will also host a conference call on the same day at 8:00 a.m. EST to discuss these results and recent business developments. Interested parties can register for the call or access a live webcast via Akebia’s investor relations website.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics (Nasdaq: AKBA) announced that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. The company will host a conference call on the same day at 8:00 a.m. EST to discuss these results and recent business highlights. Investors are required to register to receive dial-in details, and a live webcast will be available on Akebia's investor website.
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: A Potential 238% Upside in the Healthcare Sector
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on kidney diseases, is highlighted as a compelling investment opportunity with a potential upside of 238%. Despite not being currently profitable, the company shows strong revenue growth of 57% and a substantial free cash flow. Analyst sentiment is overwhelmingly positive, with an average target price of $4.60, driven by its innovative product pipeline and strategic collaborations.
AKBA: VAFSEO and pipeline progress drive growth, with major clinical catalysts expected in the next year
Akebia Therapeutics (AKBA) is projected for growth due to the increasing adoption of VAFSEO for dialysis anemia and upcoming pivotal data from VOCAL and VOICE studies. The company is also advancing pipeline assets praliciguat and AKB-097 for rare kidney diseases, with new trials initiated. Akebia maintains a strong financial position to support its ongoing development and expected clinical catalysts in the coming year.
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $4.00 at Piper Sandler
Piper Sandler lowered its price target for Akebia Therapeutics (NASDAQ:AKBA) to $4.00 from $6.00, while maintaining an "overweight" rating. This new target implies a substantial upside of approximately 191% from the stock's current trading price. The biopharmaceutical company recently saw its CAO sell over 49,000 shares, reducing insider ownership to about 3%, and trades with a market cap of around $365 million.
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "Buy" rating for Akebia Therapeutics (NASDAQ:AKBA) with a $6.00 target price, implying a significant upside. Other analysts also maintain "Buy" or "Strong Buy" ratings, resulting in a "Moderate Buy" consensus. Despite insider selling by CAO Richard Malabre, institutional investors have increased their holdings, now owning approximately 33.92% of the stock.
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, at 9:30 AM EST. The company, focused on kidney disease treatments, will have a webcast of the presentation available following the conference. The summit itself runs from February 11-12 in New York City.
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, at 9:30 AM EST. A webcast of the presentation will be available on the "Investors" section of Akebia’s website following the conference. The summit, hosted by Guggenheim Securities, LLC, is scheduled for February 11-12 in New York City.
Akebia Therapeutics to present at Guggenheim Biotech Summit
Akebia Therapeutics, Inc. has announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. The company will be presenting at this prestigious event to highlight its developments in the biotech field. This reflects Akebia's ongoing commitment to exploring industry opportunities and showcasing its advancements to potential partners and investors.
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics, Inc. announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The presentation will occur on Thursday, February 12, at 9:30 AM EST, and a webcast will be available on Akebia's website. The summit, hosted by Guggenheim Securities, LLC, is scheduled for February 11-12 in New York City.
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics, Inc. announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The summit is scheduled for February 11-12 in New York City, with Akebia's presentation taking place on Thursday, February 12 at 9:30 AM EST. A webcast of the presentation will be available on the company's investor relations website after the event.
Akebia Therapeutics reports inducement grants under Nasdaq listing rule
Akebia Therapeutics announced inducement grants under Nasdaq listing rule 5635(c)(4). The company's stock, AKBA, closed at 1.380 USD with a 5-day change of -2.13%. Akebia is a biopharmaceutical company focused on developing and commercializing therapeutics, including Auryxia and Vafseo.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced the grant of options to purchase 132,675 shares of its common stock to two new employees on January 30, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.41 per share and vest over four years, subject to continued employment.
Two Akebia hires get options on 132,675 shares at $1.41
Akebia Therapeutics granted inducement stock options for an aggregate of 132,675 shares to two new employees on January 30, 2026, with an exercise price of $1.41 per share. These options vest over four years and have a 10-year term, granted under Nasdaq Listing Rule 5635(c)(4). This move is consistent with the company's continuous efforts to attract talent and its history of granting inducement options.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced that it granted options to purchase 132,675 shares of its common stock to two newly-hired employees on January 30, 2026. These inducement grants were made under Nasdaq Listing Rule 5635(c)(4), with an exercise price of $1.41 per share, equal to the closing price on the grant date. The options vest over four years, subject to continued service.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics announced it granted stock options to two new employees on January 30, 2026, as an inducement for their employment. The grants, totaling 132,675 shares with an exercise price of $1.41 per share, were made in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, subject to continued employment.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 132,675 shares of common stock to two new employees on January 30, 2026. These inducement grants, made under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.41 per share and vest over four years. This action aligns with Akebia's mission as a biopharmaceutical company focused on kidney disease.
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions
Akebia Therapeutics, Inc. recently experienced a US$48 million market cap drop, and institutional investors, who own 50% of the company, are significantly impacted. With a total of 25 investors holding a majority stake and a 35% loss over the past year for shareholders, these institutions may be compelled to sell, potentially affecting individual investors. The article highlights that BlackRock, Inc. is the largest shareholder at 7.1%, while insiders collectively own US$7.2 million.
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions
Following a US$48 million market cap drop, Akebia Therapeutics' stock price may be vulnerable due to the significant stake held by institutional investors. These institutions collectively own 50% of the company, and their recent losses on their holdings suggest they might sell, potentially impacting individual investors. The article details the ownership breakdown, highlighting BlackRock as the largest institutional shareholder, and notes some insider ownership as well as substantial general public ownership.
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)
Akebia Therapeutics is focusing its efforts on Vafseo for dialysis patients, which has led to a recalibration of near-term growth projections after discontinuing its expansion into non-dialysis treatments. The company anticipates revenue normalization following temporary inventory reductions, driven by Vafseo's commercial momentum and broad U.S. dialysis access. Additionally, Akebia has key pipeline catalysts expected in 2026, including Phase 2 data for praliciguat and the initiation of a Phase 2 study for AKB-097, diversifying its portfolio beyond its anaemia franchise.
Akebia reports first patient dosed in rare kidney disease trial By Investing.com
Akebia Therapeutics has announced the first patient has been dosed in its Phase 2 clinical trial for praliciguat, a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Despite its stock trading near a 52-week low, the company reported securing prescribing access for its anemia treatment Vafseo to approximately 275,000 dialysis patients, expecting increased demand in 2026. Akebia plans to initiate another Phase 2 trial for AKB-097, a second rare kidney disease candidate, in the latter half of 2026.
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving Average - Here's Why
Akebia Therapeutics (NASDAQ:AKBA) shares have fallen below their 50-day moving average, dropping 7.9% to $1.40 on heavy trading volume. Despite this decline, analysts maintain a "Moderate Buy" consensus rating with a $6.00 price target. Institutional investors have significantly increased their stakes, with total institutional ownership around 33.9%.
Akebia reports first patient dosed in rare kidney disease trial
Akebia Therapeutics (NASDAQ:AKBA) has dosed the first patient in its Phase 2 clinical trial for praliciguat, targeting focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The company also announced expanded prescribing access for its anemia treatment Vafseo to around 275,000 dialysis patients and plans to initiate another Phase 2 trial for AKB-097 in late 2026 for other rare kidney diseases. Despite its stock trading near a 52-week low, Akebia expects increased demand for Vafseo and is in a solid financial position, anticipating top-line results from its VOICE trial in early 2027 and VOCAL trial data in Q4 2026.
Akebia reports first patient dosed in rare kidney disease trial By Investing.com
Akebia Therapeutics (NASDAQ:AKBA) has dosed the first patient in its Phase 2 clinical trial for praliciguat, a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The company also announced increased prescribing access for its anemia treatment Vafseo, expecting higher demand in 2026, and plans to initiate another Phase 2 trial for a different rare kidney disease candidate, AKB-097. Despite a recent stock decline, Akebia reported strong revenue growth and a shift to net income in Q3 2025.
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Akebia Therapeutics provided key updates on its Vafseo commercial business and outlined its 2026 pipeline milestones, focusing on rare kidney disease programs. The company expects increased demand for Vafseo in 2026, driven by expanded prescribing access and ongoing clinical trials aimed at establishing it as a standard of care. Additionally, Akebia advanced its Praliciguat Phase 2 clinical trial for FSGS and plans to initiate a rare kidney disease basket study for AKB-097 in the second half of 2026.
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Akebia Therapeutics provided key corporate updates for its Vafseo commercial business and outlined its 2026 pipeline milestones. The company expects increased demand for Vafseo, aiming to make it standard of care for anemia due to chronic kidney disease in dialysis, and is progressing its rare kidney disease pipeline with ongoing clinical trials for Praliciguat and AKB-097. Akebia also reported Q4 2025 Vafseo performance expectations and detailed its pipeline activities for various kidney diseases.
Akebia announces first patient dosed in Phase 2 trial of praliciguat
Akebia Therapeutics has announced that the first patient has been dosed in a Phase 2 clinical trial for praliciguat, a soluble guanylate cyclase (sGC) stimulator. This drug is being evaluated for the treatment of biopsy-confirmed FSGS, a rare kidney disease, with potential future applications for other rare podocytopathies. There are currently no approved treatments for FSGS, which impacts approximately 40,000 patients in the U.S., and praliciguat has shown no significant safety issues in previous Phase 1 and 2 studies.
New pill tested for rare kidney disease with no approved treatments
Akebia Therapeutics has initiated a Phase 2 clinical trial for praliciguat, an oral, once-daily sGC stimulator, targeting focal segmental glomerulosclerosis (FSGS), a rare kidney disease affecting approximately 40,000 patients in the U.S. with no approved treatments. The study will assess the drug's efficacy and safety in approximately 60 adults, with the primary endpoint being the change in urine protein-to-creatinine ratio (UPCR) at Week 24. This marks a significant step in Akebia's mid-stage rare kidney disease pipeline, building on previous Phase 1 and Phase 2 studies that showed no significant safety issues.
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat
Akebia Therapeutics (AKBA) has begun a Phase 2 clinical trial for its kidney disease drug, praliciguat, with the first patient now dosed. Praliciguat is an orally administered investigational compound designed to address cardiorenal disease. This move signifies a key advancement in Akebia's pipeline, expanding its focus into rare kidney diseases.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics has announced that the first patient has been dosed in its Phase 2 clinical trial for praliciguat, a drug aimed at treating Focal Segmental Glomerulosclerosis (FSGS). This rare kidney disease currently has no approved treatments, affecting approximately 40,000 patients in the U.S. Praliciguat, an oral soluble guanylate cyclase stimulator, has shown a promising safety profile in previous Phase 1 and Phase 2 studies for other conditions.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics announced the dosing of the first patient in a Phase 2 clinical trial for praliciguat, an oral soluble guanylate cyclase stimulator, targeting Focal Segmental Glomerulosclerosis (FSGS). FSGS is a rare kidney disease affecting approximately 40,000 patients in the U.S. with no approved treatments. The study will evaluate praliciguat's efficacy and safety, with the primary endpoint being the change in urine protein-to-creatinine ratio at Week 24.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no approved treatments. The randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of praliciguat in approximately 60 adult FSGS patients, with the primary endpoint being the change from baseline in urine protein-to-creatinine ratio (UPCR) at Week 24. Praliciguat, licensed from Cyclerion Therapeutics, has shown no significant safety issues in previous Phase 1 and Phase 2 studies.
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a biopharmaceutical firm focused on developing and commercializing therapeutics, including Auryxia (ferric citrate) and Vafseo (vadadustat), for kidney disease and related conditions. Akebia also reported recent news, including the dosing of the first patient in a Phase 2 clinical trial for Praliciguat.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts
Akebia Therapeutics, Inc. (NASDAQ:AKBA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month target price of $6.00. Institutional investors are increasing their stakes, and the company, focused on kidney disease therapies, opened at $1.55 with a market capitalization of $411.3 million. The stock trades with a 50-day SMA of $1.76 and a 200-day SMA of $2.74.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted options to purchase 197,900 shares of its common stock to a newly-hired employee on December 31, 2025, as an inducement to employment. These options have an exercise price of $1.61 per share and vest over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, headquartered in Cambridge, Massachusetts.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted stock options to a newly-hired employee to purchase 197,900 shares of its common stock. These options, granted on December 31, 2025, serve as an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.61 per share and vest over four years, contingent on continuous service.
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
U.S. Renal Care has enrolled the first patients in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. This study will assess Vafseo's efficacy and safety in chronic kidney disease patients on dialysis, comparing it to the standard of care as it prepares for its anticipated market launch in January 2025. The trial's primary and secondary endpoints focus on all-cause mortality and all-cause hospitalization, respectively.
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Akebia Therapeutics (NASDAQ: AKBA) is expanding its focus beyond anemia with a new rare kidney disease pipeline, featuring AKB-097, a next-generation complement inhibitor, and praliciguat, an sGC stimulator. This move aligns with the company's strategy to establish Vafseo for anemia while building a robust pipeline for rare kidney conditions, having recently acquired global rights to ADX-097 (now AKB-097) from Q32 Bio Inc. AKB-097 offers targeted complement inhibition at the organ level, distinguishing it from systemic inhibitors.
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Akebia Therapeutics (NASDAQ: AKBA) has announced the establishment of a new rare kidney disease pipeline, expanding beyond its focus on anemia. This new pipeline features two key product candidates: AKB-097, a next-generation complement inhibitor, and praliciguat, an sGC stimulator, complementing its existing Vafseo treatment for anemia in dialysis patients. The expansion follows Akebia's acquisition of global rights to ADX-097 (now AKB-097) from Q32 Bio Inc.
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) has granted stock options to four new employees as an inducement material to their employment. These options cover a total of 137,000 shares of common stock, with an exercise price of $1.52 per share, which was the closing price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the subsequent three years.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts
Akebia Therapeutics, Inc. (NASDAQ:AKBA) has received a consensus "Moderate Buy" rating from the eight research firms currently covering the company, with an average 1-year target price of $6.00. Analyst ratings range from "sell" to "strong buy," reflecting varied expert opinions. The stock's recent performance shows a market capitalization of $432.55 million and analysts have reiterated and adjusted ratings following recent developments.
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Akebia Therapeutics, Inc. (AKBA) shareholders due to a significant stock price drop following the company's announcement regarding the FDA's lack of alignment on the VALOR clinical trial design. This trial concerned the use of vadadustat for treating anemia in non-dialysis dependent CKD patients, which Akebia will no longer pursue. Investors are encouraged to contact the firm for more information regarding the securities investigation.
Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics
Q32 Bio, Inc. has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. The deal includes $12 million in upfront and near-term milestone payments, with potential milestones totaling up to $592 million, plus tiered royalties. This transaction extends Q32 Bio's operational funding into the second half of 2027, allowing for continued development of its other tissue-targeted complement inhibitor programs.
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32
Akebia Therapeutics has acquired a Phase II alopecia areata candidate from Q32 Bio. This deal highlights Q32's strategic cost-conscious approach, opting to license out assets rather than advancing them independently. The acquisition strengthens Akebia's pipeline with a promising new therapeutic area.
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Akebia Therapeutics (NASDAQ:AKBA) and set a price target of $6.00, suggesting a significant upside of 298.7% from its current share price. The biopharmaceutical company's stock currently holds a "Moderate Buy" consensus rating from analysts, with its lead drug, Vafseo (vadadustat), in Phase III development for chronic kidney disease-related anemia. Despite mixed analyst coverage, including both Strong Buy and Sell ratings, institutional investors own approximately 33.92% of the stock.
Geode Capital Management LLC Acquires 1,043,718 Shares of Akebia Therapeutics, Inc. $AKBA
Geode Capital Management LLC increased its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 20.7%, acquiring an additional 1,043,718 shares, bringing its total holdings to 6,074,458 shares valued at approximately $22.12 million. Several other institutional investors also adjusted their positions in the biopharmaceutical company. Analyst ratings for Akebia Therapeutics are mixed, with a consensus of a "Moderate Buy" and an average price target of $6.00.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted stock options to two new employees to purchase an aggregate of 22,576 shares of common stock. These options, granted on November 28, 2025, are an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4), vesting over four years. The exercise price is $1.58 per share, matching the closing price on the grant date.
Akebia Therapeutics (Nasdaq: AKBA) announces 22,576-share inducement grant
Akebia Therapeutics (Nasdaq: AKBA) has granted inducement stock options for 22,576 shares to two new employees on November 28, 2025, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.58 per share, matching the closing price on the grant date. These options will vest over four years, with 25% vesting after one year and the remainder vesting quarterly, and have a 10-year term.
